2026 年至 2032 年肌少症治疗市场（依治疗类型、给药途径、最终使用者和地区划分）

2026-2032 年肌少症治疗市场评估

肌少症是一种导致肌肉质量和力量下降的疾病，严重影响老年人的生活品质。随着人口老化，人们对肌少症的不良健康影响以及早期发现和管理的重要性的认识不断提高，这推动了对有效治疗方法和干预措施的需求。根据 Verified Market Research 分析师预测，肌少症治疗市场规模将从 2024 年的约 2.8946 亿美元下降至预测期内的 4.4423 亿美元。

此外，持续的研究和开发努力正在推动新治疗方法，医疗保健专业人员和患者对这种与老龄化相关的疾病的有效治疗方法的需求正在加速市场扩张，预计从 2026 年到 2032 年，复合年增长率将达到 5.5%。

肌少症治疗市场定义/概述

肌少症治疗包括一系列旨在预防、管理和缓解肌少症的产品和服务。肌少症退化性疾病，其特征是骨骼肌质量、力量和功能下降，尤其常见于老年人。治疗策略可能包括营养干预，例如补充蛋白质、维生素和矿物质，以及阻力训练和物理治疗，以增强力量和功能。治疗肌少症可以降低跌倒和骨折的风险，提高运动能力，管理相关的代谢紊乱，支持更健康的老龄化，并维持日常活动的独立性，从而改善老年人的生活品质。

影响肌少症治疗市场成长的市场驱动因素有哪些？

全球老龄人口的成长是肌少症治疗市场的主要驱动力。根据世界卫生组织 (WHO) 的数据，2015 年至 2050 年期间，全球 60 岁及以上人口的比例将几乎翻一番，从 12% 增加到 22%。到 2050 年，80% 的老年人将生活在中低收入国家。这种人口结构变化至关重要，因为肌少症主要发生在老年人身上。根据国际骨质疏鬆症基金会的数据，肌少症影响约 10% 的 60 岁及以上族群，而 80 岁及以上族群的发生率则上升至 50%。

慢性疾病可导致或加重肌少症，进而增加治疗需求。根据美国美国10 人中就有 6 人患有至少一种慢性疾病，每 10 人中就有 4 人患有两种或两种以上的慢性疾病。糖尿病影响全球约 4.63 亿成年人，它会加速肌肉流失。研究表明，2 型糖尿病患者的肌少症发生率比非糖尿病患者高 15%。

此外，医疗保健专业人员意识的不断提升以及更先进诊断工具的开发，也推动了肌少症治疗市场的发展。 2018年，欧洲老年人肌少症工作小组 (EWGSOP) 修订了肌少症的定义和诊断标准，从而提高了诊断的准确性。根据发表在《恶病质、肌少症和肌肉》杂誌上的一项研究，当使用更新的 EWGSOP2 标准替代原标准时，肌少症的盛行率从 12.9% 上升至 17.7%。这项诊断改进预计将增加肌肉减少症治疗的需求。

实施肌少症治疗的主要挑战是什么？

肌少症治疗和疗法的高昂成本对市场构成了重大挑战。许多有效的治疗方法，例如营养补充剂和专科药物，价格高昂，因此很大一部分老年人口无法负担。这种经济障碍阻碍了患者寻求治疗或遵守处方方案，从而降低了肌少症治疗的整体效果，并限制了市场扩张。

此外，与老龄化相关的社会观念和污名化也构成了治疗的障碍。许多人由于对老龄化的误解以及认为肌肉流失是老化不可避免的一部分而不愿寻求肌肉减少症的治疗。这导致人们对治疗肌少症的必要性缺乏认识，从而导致诊断不足和治疗不足，限制了市场的成长潜力。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章 肌少症治疗市场（依治疗类型）

• 蛋白质补充剂
• 维生素B12补充剂
• 维生素 D 和钙补充剂
• 其他的

第五章 肌少症治疗市场（依给药途径）

• 口服
• 注射
• 其他的

第六章 肌少症治疗市场（依最终使用者划分）

• 医院
• 药局和零售药局
• 网路药局

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市场占有率分析

第十章 公司简介

• Nestle Health Science
• Sanofi SA
• Bayer AG
• Haleon Group of Companies
• Novartis AG
• Abbott Laboratories
• Metagenics LLC
• Pfizer Inc.
• GlaxoSmithKline plc.
• Makers Nutrition LLC

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Sarcopenia Treatment Market Valuation - 2026-2032

The world's aging population is the main factor driving the sarcopenia treatment market since it raises the prevalence of the ailment, which lowers muscle mass and strength and has a serious negative impact on the quality of life for the elderly. As more people age, the demand for effective therapies and interventions grows, driven by increased knowledge of sarcopenia's negative health impacts and the importance of early detection and management. According to the analyst from Verified Market Research, the sarcopenia treatment market is estimated to reach a valuation of USD 444.23 Million over the forecast subjugating around USD 289.46 Million valued in 2024.

Furthermore, continuing research and development efforts are yielding new therapeutic alternatives, accelerating market expansion as healthcare practitioners and patients seek effective treatments for this age-related illness. It enables the market to grow at a CAGR of 5.5% from 2026 to 2032.

Sarcopenia Treatment Market: Definition/Overview

Sarcopenia treatment includes a variety of products and services aimed at preventing, managing, or alleviating sarcopenia, a degenerative disorder characterized by the loss of skeletal muscle mass, strength, and function, especially in older persons. Treatment strategies include nutritional interventions, such as protein, vitamin, and mineral supplements, as well as resistance training and physical therapies to improve muscular strength and functionality. Sarcopenia treatment can improve the quality of life for the aged by lowering the risk of falls and fractures, increasing mobility, managing associated metabolic disorders, supporting healthier aging, and preserving independence in everyday activities.

What are the Drivers Influencing the Growth of the Sarcopenia Treatment Market?

The growing older population worldwide is a major driver of the sarcopenia treatment market. According to the World Health Organization (WHO), the proportion of the global population over the age of 60 will nearly double between 2015 and 2050, from 12% to 22%. By 2050, 80% of the elderly will live in low- and middle-income countries. This demographic shift is critical since sarcopenia primarily affects elderly people. According to the International Osteoporosis Foundation, sarcopenia affects about 10% of those over the age of 60, with the frequency increasing to 50% in those over the age of 80.

Chronic conditions lead to or aggravate sarcopenia, increasing the need for treatment. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 persons in the United States have at least one chronic disease, with 4 in 10 having two or more. Diabetes, which affects around 463 million adults globally, can speed up muscle loss. Sarcopenia is 15% more common in persons with type 2 diabetes than in those without the disease, according to studies.

Furthermore, the growing awareness among healthcare professionals and the development of better diagnostic tools are propelling the sarcopenia treatment market. In 2018, the European Working Group on Sarcopenia in Older People (EWGSOP) modified its definition and diagnostic criteria for sarcopenia, resulting in more accurate identification of the condition. According to a study published in the Journal of Cachexia, Sarcopenia and Muscle, the prevalence of sarcopenia increased from 12.9% to 17.7% when the updated EWGSOP2 criteria were used instead of the original criteria. This enhanced diagnosis is projected to increase the demand for sarcopenia treatments.

What are the Key Challenges Associated with Adopting Sarcopenia Treatment?

The high expense of sarcopenia treatment and therapies presents a significant challenge for the market. Many effective therapies, such as nutritional supplements and specialist pharmaceuticals, are prohibitively expensive, making them inaccessible to a large percentage of the senior population. This financial barrier discouraged patients from seeking treatment or sticking to prescribed regimens, reducing the overall effectiveness of sarcopenia care and restricting market expansion.

Furthermore, social beliefs and stigmas associated with aging serve as a barrier to treatment. Many people are hesitant to seek treatment for sarcopenia because of misconceptions about aging and the belief that muscle loss is an unavoidable part of growing older. This hesitation leads to underdiagnosis and undertreatment, as those affected fail to grasp the need to tackle sarcopenia, limiting the market's growth potential.

Category-wise Acumens

How Does the Dominance of the Vitamin D & Calcium Supplements Segment Propel the Market?

According to VMR analyst, the vitamin D & calcium supplement segment is anticipated to dominate the segment within the sarcopenia treatment market during the forecast period. The importance of Vitamin D in muscular health adds greatly to the segment's prominence. Vitamin D is required for calcium absorption and bone metabolism, which are critical for muscular function. According to research, adequate levels of Vitamin D can help minimize the incidence of sarcopenia, especially in older persons, resulting in growing demand for these supplements as muscle loss prevention strategies.

The increasing knowledge of sarcopenia's negative effects on health is another driver of the market. As more people become aware of the problems connected with muscle loss, there is a greater emphasis on nutritional solutions to counteract the condition. Vitamin D and calcium supplements are highlighted in educational efforts directed at older persons, driving their usage as part of a proactive strategy to preserve muscle strength and overall health.

Furthermore, the rising prevalence of Vitamin D deficiency among the elderly is a major factor driving demand for Vitamin D and calcium supplements. Many older persons have low Vitamin D levels because of restricted sun exposure and nutritional intake, so supplementation is an important technique for preventing sarcopenia. The increased knowledge of deficiency-related hazards has resulted in a spike in demand for these specific supplements as effective treatment options.

How does the Increasing Hospitalization Rates Contribute to the Demand for Hospitals?

The hospital segment is estimated to hold the largest share of the sarcopenia treatment market during the forecast period. The rising hospitalization rates of elderly people experiencing problems from sarcopenia are a major contributing factor. As the population ages, more people may need medical attention for falls, fractures, and other muscle-related health concerns. Hospitals have an important role in delivering complete care, including diagnosis, treatment, and rehabilitation, which increases the demand for sarcopenia treatments in these settings.

Hospitals' domination is further aided by the availability of specialized healthcare professionals and resources. Hospitals have interdisciplinary teams of geriatricians, dietitians, and physical therapists who can work together to meet the complicated needs of sarcopenic patients. This comprehensive strategy improves treatment efficacy and patient outcomes, making hospitals the optimal setting for managing sarcopenia.

Furthermore, insurance coverage and reimbursement policies frequently favor hospital-based therapies, making them more accessible for patients. Many health insurance policies offer better coverage for hospital-administered treatments than those bought from pharmacy stores or online pharmacies. This financial incentive encourages patients to seek therapy in hospitals, reinforcing the hospital segment's dominant position in the sarcopenia treatment market.

Country/Region-wise Acumens

How Does the High Prevalence of Chronic Diseases Associated with Sarcopenia in Asia Pacific Propel the Market?

According to VMR analysis, the Asia Pacific region is estimated to dominate in sarcopenia treatment market during the forecast period. The Asia Pacific area has a high prevalence of chronic diseases related to sarcopenia, which drives the market. According to the International Diabetes Federation, the Western Pacific region (which comprises the majority of East Asia and Oceania) had the highest number of diabetic adults (163 million) in 2019. This number is predicted to increase to 212 million by 2045. Diabetes is known to accelerate muscle loss, with research indicating that the prevalence of sarcopenia in Asian people with type 2 diabetes is approximately 14.8%, which is much greater than in non-diabetic persons.

Furthermore, the growing healthcare spending and improved diagnostic capabilities in the Asia Pacific region are propelling the sarcopenia treatment market. According to the World Bank, health spending per capita in East Asia and the Pacific rose from $571 in 2010 to $937 in 2019, showing a growing investment in healthcare. In China, one of the region's largest marketplaces, health spending per capita has more than doubled, from $289 in 2010 to $731 in 2019. This increased funding allows for better detection and treatment of illnesses such as sarcopenia.

What are the Drivers Bolstering the Sarcopenia Treatment Market in North America?

North America is estimated to exhibit substantial growth within the market during the forecast period. North America has a huge and expanding older population, which drives the sarcopenia treatment market. According to the United States Census Bureau, the number of Americans aged 65 and up is expected to nearly double, from 52 million in 2018 to 95 million by 2060. Sarcopenia is highly prevalent in North America. According to a study published in the Journal of Cachexia, Sarcopenia, and Muscle, the prevalence of sarcopenia in the United States varies between 10% and 40% among persons aged 60 and older, depending on the diagnostic criteria utilized. This high frequency indicates a sizable market for sarcopenia treatments.

Furthermore, North America, particularly the United States, has high rates of obesity and accompanying metabolic problems, which are directly tied to sarcopenia. According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence in the United States was 42.4% in 2017-2018. According to data from the National Health and Nutrition Examination Survey (NHANES), the prevalence of sarcopenic obesity among older persons in the United States ranges from 4% to 25%, depending on the definition. The increased incidence of obesity, particularly sarcopenic obesity, is driving the need for comprehensive sarcopenia treatments that target both muscle loss and metabolic health.

Competitive Landscape

The sarcopenia treatment market is competitive, with several significant competitors contending for market share. Large companies are focusing on strategic initiatives such as new product launches, mergers and acquisitions, and research and development efforts to increase their market position.

Some of the prominent players operating in the sarcopenia treatment market include:

Nestle Health Science

Sanofi S.A.

Bayer AG

Haleon Group of Companies

Novartis AG

Abbott Laboratories

Metagenics LLC

Pfizer, Inc.

GlaxoSmithKline plc.

Makers Nutrition LLC

Latest Developments:

In July 2024, Abbott Laboratories launched clinical research to assess the efficacy of its novel protein supplement designed exclusively for sarcopenia sufferers. The study's goal is to examine improvements in muscle strength and functionality among older persons, reinforcing Abbott's emphasis on new solutions to age-related health issues.

In June 2024, Pfizer Inc. announced a collaboration with various academic institutions to enhance sarcopenia research. This collaboration intends to investigate the potential of new pharmacological therapy paired with nutritional interventions, demonstrating Pfizer's commitment to addressing the growing concerns about muscle loss in the elderly population.

Sarcopenia Treatment Market, by Category

Treatment Type:

Protein Supplements

Vitamin B12 Supplements

Vitamin D & Calcium Supplements

Others

Route of Administration:

Oral

Injectable

Others

End-User:

Hospitals

Drug Stores and Retail Pharmacies

Online Pharmacies

Region:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Sarcopenia Treatment Market, By Treatment Type

• Protein Supplements
• Vitamin B12 Supplements
• Vitamin D & Calcium Supplements
• Others

5. Sarcopenia Treatment Market, By Route of Administration

• Oral
• Injectable
• Others

6. Sarcopenia Treatment Market, By End-User

• Hospitals
• Drug Stores and Retail Pharmacies
• Online Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Nestle Health Science
• Sanofi S.A.
• Bayer AG
• Haleon Group of Companies
• Novartis AG
• Abbott Laboratories
• Metagenics LLC
• Pfizer Inc.
• GlaxoSmithKline plc.
• Makers Nutrition LLC

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References